Literatur
- 1
.
Early Breast Cancer Trialists Collaborative Group
Polychemotherapy for early breast cancer: an overview of the randomised
trials.
The Lancet.
1998;
352
930-942
- 2
Early Breast Cancer Trialists Collaborative Group Tamoxifen
for early breast cancer: an overview of the randomised trials.
The Lancet.
1998;
351
1451-1467
- 3
Budman D. R., Berry D. A., Cirrincione C. T., Henderson I. C.. et al. .
Dose and dose intensity as determinants of outcome in the
adjuvant treatment of breast cancer.
JNCI.
1998;
90
1205-1211
- 4
Misset J.-L., DiPalma M., Delgado M.. et al. .
Adjuvant treatment of node-positive breast cancer with
cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus
cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year
median follow-up duration.
J Clin Oncol.
1996;
14
1136-1145
- 5
Fisher B., Redmond C., Wickerham D. L.. et al. .
Doxorubicin containing regimens for the treatment of stage II
breast cancer: The National Surgical Breast and Bowel Project Experience.
J Clin Oncol.
1989;
7
572-582
- 6
Fisher B., Brown A. M., Dimitrov N. V., Poisson R., Redmond C.. et al. .
Two months of doxorubicin-cyclophosphamide with and without
reinduction therapy compared with 6 months of cyclophosphamide, methotrexate,
and fluorouracil in positivenode breast cancer patients with
tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant
Breast and Bowel Project B-15.
J Clin Oncol.
1990;
8
1483-1496
- 7
Moliterni A., Bonadonna G., Valagussa P., Ferrari L., Zambetti M..
Cyclophosphamide, methotrexate, and fluorouracil with and
without doxorubicin in the adjuvant treatment of resectable breast cancer with
one to three positive axillary nodes.
J Clin Oncol.
1991;
9
1124-1130
- 8
Budd G. T., Green S., Martino S.. et al. .
Short course FAC-M vs. 1 year of CMFVP in nodepositive
hormonereceptor negative breast cancer: an Intergroup study.
J Clin Oncol.
1995;
13
831-839
- 9
Coombes R. C., Bliss J. M., Wils J., Morvan F., Espié M., Amadori D.. et al. .
Adjuvant cyclophosphamide, methotrexate, and fluorouracil
versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in
premenopausal women with axillary nodepositive operable breast cancer: Results
of a randomized trial.
J Clin Oncol .
1996;
14
35-45
- 10
Carpenter J. T., Velez-Garcia E., Aron B. S., Salter M.., Stahl D. L., Estes N.. et
al. .
Fiveyear results of a randomized comparison of
cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) vs.
cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast
cancer: A Southeastern Cancer Study Group Study.
Proc ASCO.
1994;
13
abstract 68
- 11
Bonadonna G., Valagussa P..
Doseresponse effect of adjuvant chemotherapy in breast
cancer.
N Engl J Med.
304
10-15
- 12
Hryniuk W., Levine M. N..
Analysis of dose intensity for adjuvant chemotherapy trials
in stage II breast cancer.
J Clin Oncol.
4
1162-1170
- 13
Fisher B., Anderson S., Wickerham D. L., DeCillis A., Dimitrov N., Mamounas E.. et
al. .
Increased intensification and total dose of cyclpphosphamide
in a doxorubicincyclophosphamide regimen for the treatment of primary breast
cancer: Findings from National Surgical Adjuvant Breast and Bowel Project
B-22.
J Clin Oncol.
1997;
15
1858-1869
- 14
Levine M., Bramwell V., Pritchard K., Shepherd L..
CEF versus CMF in premenopausal women - Recent update.
Eur J Cancer.
(Suppl. 1)
1998;
34
S 9
- 15
Bonneterre J., Roché H., Bremond A., Kerbrat P., Namer M., Fumoleau P.. et al. .
A randomized trial of adjuvant chemotherapy with FEC 50 vs.
FEC 100 for nodepositive operable breast cancer early report.
Proc ASCO .
1996;
15
abstract 82
- 16
Galligioni E., Cetto G., Nascimben O., Buonadonna A., Crivellari D., Molino A.. et
al. .
High dose epirubicin and cyclophosphamide (EC) vs
cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy
in
high risk premenopausal breast cancer patients (PTS).
A prospective randomized trial.
Eur J Cancer .
1998;
(suppl. 1)
34
S 36
- 17
Norton L., Simon R..
The Norton-Simon hypothesis revisited.
Cancer Treat Rep.
1986;
70
163-169
- 18 Gilewski T., Norton L.. Cytokinetics and breast cancer chemotherapy. In: Diseases
of the Breast, Eds.: Harris, J.R., Lippman,
M.E., Morrow, M., Hellmann, S. Lippincott-Raven, Philadelphia-New York 1996:
751-768
- 19
Bonadonna G., Zambetti M., Valagussa P..
Sequential or alternating doxorubicin and CMF regimens in
breast cancer with more than three positive nodes. Tenyear results.
JAMA.
1995;
273
542-547
- 20
Perloff M., Norton L., Korzun A H., Wood W. C., Carey R. W., Gottlieb A.. et al. .
Postsurgical adjuvant chemotherapy of stage II breast
carcinoma with or without crossover to a non-cross-resistant regimen: A Cancer
and Leukemia Group B Study.
J Clin Oncol.
1996;
14
1589-1598
- 21
Henderson I. C., Berry D., Demetri G., Cirrincione C. . et al. .
Improved disease-free (DFS) and overall survival (OS) from
the addition of sequential paclitaxel (T) but not from the escalation of
doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with
nodepositive primary breast cancer (BC).
Proc ASCO.
1998;
17
390A
- 22
.
International Breast Cancer Study Group.
Late effects of adjuvant oophorectomy and chemotherapy
upon premenopausal breast cancer patients.
Ann Oncol.
1990;
1
30-35
- 23
Kaufmann M., Jonat W., Abel U..
Adjuvant Chemo- and Endocrine Therapy Alone or in Combination
in Premenopausal Patients (GABG-Trial 1).
Recent Res Cancer Res.
1989;
115
118-125
- 24 abstract Fisher ASCO 1997
- 25
Mauriac L.. et al. .
Adjuvant trial for stage II receptor positive breast cancer:
CMF vs CMF + tamoxifen in a single center.
Br Cancer Res Treat.
1988;
11
179-186
- 26
Boccardo F.. et al. .
Chemotherapy versus tamoxifen versus chemotherapy plus
tamoxifen in nodepositive, estrogen receptorpositive breast cancer patients:
results of a multicentric Italian study.
J clin Oncol.
1990;
1990.
8
1310-1320
- 27
Fisher B., Redmond C., Legault-Poisson S., Dimitrov N. V., Brown A. M., Wickerham D. L..
et al. .
Postoperative chemotherapy and tamoxifen compared with
tamoxifen alone in the treatment of positivenode breast cancer patients aged
50
years and older with tumors responsive to tamoxifen: results from the National
Surgical Adjuvant Breast and Bowel Project B-16.
J Clin Oncol.
1990;
8
1005-1018
- 28
Wils J., Bliss J . M., Coombes R. C., Woods E., Coombes G., Blijham G. H.. et al.
.
A multicenter randomized trial of Tamoxifen vs.Tamoxifen plus
Epirubicin in postmenopausal women with nodepositive breast cancer.
Proc ASCO.
1996;
15
abstract 101
- 29
Albain K., Green S., Osborne K., Cobau C., Levine E., Ingle J.. et al. .
Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU
plus either concurrent or sequential T in postmenopausal, receptor(+), node(+)
breast cancer: a Southwest Oncology Group phase III intergroup trial
(SWOG-8814, INT-0100).
Proc ASCO.
1997;
16
abstract 450
- 30
The International Breast Cancer Study Group.
Effectiveness of adjuvant chemotherapy in combination
with Tamoxifen for nodepositive postmenopausal breast cancer patients.
Clin Oncol.
1997;
15
1385-1394
Korrespondenzadresse:
Prof. Dr. med. Volker Möbus
Städtische KlinikenFrauenklinik
Gotenstr. 6-8
65929 Frankfurt a.M.
